88 results on '"Delforge, Michel"'
Search Results
2. Polyneuropathie in de CASSIOPEIA-studie
3. Health-related quality of life in patients with relapsed/refractory multiple myeloma (RRMM) treated with teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody: Patient-reported outcomes in MajesTEC-1
4. Additional file 1 of Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study
5. Additional file 2 of Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study
6. Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study
7. COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network
8. Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up
9. COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network
10. Insights on multiple myeloma treatment strategies
11. Characterization of Relapse and Second-Line Therapy in Lenalidomide-Refractory, Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma: A Subanalysis of the Phase 3 First Trial
12. Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Treated with Isatuximab Plus Pomalidomide and Dexamethasone: Icaria-MM Study
13. Phase 2b results of the STORM study: oral selinexor plus low dose dexamethasone (SD) in patients with penta-refractory myeloma (Penta-MM)
14. Bortezomib-based therapy for relapsed/refractory multiple myeloma in real-world medical practice
15. Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network
16. Diagnostic thresholds for free light chains in multiple myeloma depend on the assay used (epub ahead of print)
17. Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis
18. Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma
19. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma
20. (clone) Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
21. Analysis of renal impairment in MM-003, a phase III study of pomalidomide+ low-dose dexamethasone versus high-dose dexamethasone in refractory or relapsed and refractory multiple myeloma
22. MANAGEMENT OF ADVERSE EVENTS IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA TREATED WITH POMALIDOMIDE PLUS LOW-DOSE DEXAMETHASONE: A POOLED SAFETY ANALYSIS OF 3 CLINICAL TRIALS
23. Final analysis of overall survival from the first trial
24. Two Cases of Heavy Chain MGUS
25. Adverse event (AE) management in patients (pts) with relapsed and refractory multiple myeloma (RRMM) taking pomalidomide (POM) plus low dose-dexamethasone (LoDEX): A pooled analysis from 3 clinical trials
26. Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma
27. Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials
28. Practical considerations for the use of daratumumab, a novel CD38 monoclonal antibody, in myeloma
29. Multiple myeloma
30. Extended follow-up of High-dose Melphalan and autologous SCT after Vincristine, Doxorubicin, Dexamethasone induction in AL amyloidosis of the prospective phase II HOVON-41 study by the Dutch-Belgian Cooperative Trial Group for Hematology Oncology
31. Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone
32. Analysis of patients with refractory or relapsed and refractory multiple myeloma and renal impairment treated with pomalidomide+ low-dose dexamethasone in the phase 3B STRATUS trial (MM-010)
33. Outcomes for older patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide plus low-dose dexamethasone in the Stratus (MM-010) trial, a single-arm, phase 3b study
34. An Updated Analysis of the Stratus Trial (MM-010): Safety and Efficacy of Pomalidomide Plus Low-Dose Dexamethasone (POM plus LoDEX) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
35. Health resource utilization with continuous lenalidomide treatment (TX) in elderly patients with newly diagnosed multiple myeloma (NDMM)
36. Impact of continuous treatment vs fixed duration of therapy in newly diagnosed myeloma patients: pFS1, PFS2, OS endpoints
37. MM-003, A PHASE 3 STUDY OF POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE VS. HIGH-DOSE DEXAMETHASONE IN REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA: OUTCOMES BY PRIOR THERAPY AND RESPONSE DEPTH
38. IMPACT OF ECOG PERFORMANCE STATUS ON OVERALL SURVIVAL AND HRQOL IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS FROM THE MM-003 TRIAL OF POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE (DEX) vs HIGH-DOSE DEX
39. Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged≥ 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trial
40. The STRATUS trial (MM-010): A single-arm phase 3b study of pomalidomide plus low-dose dexamethasone (POM plus LoDEX) in refractory or relapsed and refractory multiple myeloma
41. Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma
42. Inverse Probability of Censoring Weighted Analysis to Adjust the Treatment Effect on Overall Survival for Subsequent Therapy: A Case Study in a Clinical Trial in Multiple Myeloma
43. CYTOGENETICS AND LONG-TERM SURVIVAL IN MM-003, A PHASE 3 TRIAL OF POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE VS. HIGH-DOSE DEXAMETHASONE IN REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA
44. Outcomes for Older Patients in Stratus (MM-010), a Single-Arm, and Phase 3b Study of Pomalidomide plus Low-Dose Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma
45. PHASE 3 STUDY OF POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE VS. HIGH-DOSE DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: MM-003 SUBANALYSIS OF ELDERLY PATIENTS (> 65 AND> 70 YEARS OF AGE)
46. European perspective on multiple myeloma treatment strategies in 2014
47. Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial
48. maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial
49. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
50. MM-003 phase 3 study of pomalidomide in combination with low-dose dexamethasone (POM+ LoDEX) vs high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM): POM+ LoDEX is beneficial for elderly patients (> 65 years of age)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.